The global hyperlipidemia drugs market size is calculated at USD 24.47 billion in 2025 and is expected to reach around USD 31.49 billion by 2034, growing at a CAGR of 2.84% for the forecasted period.
Ottawa, Feb. 21, 2025 (GLOBE NEWSWIRE) — The global hyperlipidemia drugs market size was valued at USD 23.8 billion in 2024 and is predicted to hit around USD 30.62 billion by 2033, a study published by Towards Healthcare a sister firm of Precedence Statistics.
Get All the Details in Our Solutions – Download Brochure: https://www.towardshealthcare.com/download-brochure/5418
Market Overview and Key Statistics
The word “hyperlipidemia” refers to a group of inherited and acquired conditions that are characterized by high amounts of lipids in the body. It is a relatively prevalent illness worldwide, but particularly in the Western Hemisphere. There are already over three million persons in the U.S. and Europe who have been diagnosed with hyperlipidemia, and the number is rapidly increasing. Patients with premature coronary artery disease (CAD), which is defined as CAD that develops in males before the age of 55 to 60 and in females before the age of 65, have the greatest degree of hyperlipidemia. The incidence of hyperlipidemia is around 75–85% under the previously mentioned conditions, compared to approximately 40–48% in the control group of the same age but without early coronary artery disease.
Driving Factors for Market Growth
Rising awareness
Another major factor propelling the expansion of the hyperlipidemia medication market is the growing awareness of hyperlipidemia. Although hyperlipidemia was formerly frequently misdiagnosed or underdiagnosed, knowledge of the illness and its dangers is gradually rising. Healthcare organizations’ teaching programs and public health campaigns are partly to blame for this. The need for medications to treat hyperlipidemia is rising as more individuals become aware of the problem.
Development of better drugs
Another major factor propelling the expansion of the hyperlipidemia medication market is the creation of novel, more potent medications. Many novel medications for the treatment of hyperlipidemia have been licensed in recent years. These medications have fewer adverse effects and are more effective than previous ones. This is increasing their appeal to doctors and patients and propelling the market’s expansion.
Rising cardiovascular diseases
One major driver propelling the market is the increasing incidence of cardiovascular illnesses. For example, coronary artery disease (CAD) is the top cause of death in the United States, accounting for around 6,10,000 fatalities yearly (about 1 in 4 deaths), according to research released by the National Library of Medicine in January 2024. Additionally, it is linked to 17.8 million fatalities each year and is the third most common cause of death globally. This emphasizes how important it is to have efficient medications for hyperlipidemia in order to control lipid levels and lower the risk of cardiovascular events.
You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com
Opportunities in the Hyperlipidemia Drugs Market
- In December 2024, as it increases production of its popular diabetes and weight-loss medications, Eli Lilly & Co. is investing an additional $3 billion to expand its manufacturing presence in the United States. Construction is anticipated to start next year on the most recent investment, which is the largest outside of the company’s home state of Indiana. It will expand a recently acquired production factory in Wisconsin.
- In June 2024, launched with $190 million in combined Series A and B financings, Marea Therapeutics is a clinical-stage biotechnology firm that Third Rock Ventures is incubating to create a new generation of medications for cardiometabolic illnesses.
Regional Insights
Rising cases of obesity are driving North America.
North America held the largest share of the hyperlipidemia drugs market in 2024. Because of the rising incidence of hypercholesteremia, rising healthcare costs, and an established healthcare system, North America is anticipated to have a significant market position in the worldwide market for hyperlipidemia drugs. Furthermore, the rise in obesity in this area, which has led to the use of medications for hyperlipidemia diagnosis, is also expected to support market expansion. Problems with overweight and obesity impact one in five kids and teenagers. According to the research, over 14.7 million children and adolescents were afflicted by the 19.7% prevalence of obesity.
Additionally, it is anticipated that rising healthcare costs in the U.S. would fuel hyperlipidemia drugs market demand in this area. The United States Centers for Medicare & Medicaid Services National Health Expenditure Data 2020 states that healthcare spending increased from 9.7% to USD 4.1 trillion in 2020, or approximately 19.7% of GDP. By 2028, it is anticipated that the spending would have reached USD 6.2 trillion. Over the course of the study’s projected period, the increase in healthcare spending in the US area is probably going to spur market expansion.
Cardiovascular disease (CVD) continues to be the biggest cause of mortality in the United States, accounting for about 7.2 million fatalities per year and a significant contributor to disability despite advancements in medical technology. The anticipated yearly direct and indirect expenses of stroke and CVD were over $310 billion in 2011–2012, and they are expected to nearly triple from 2010–2030, from $273 billion to $818 billion.
Get the latest insights on healthcare industry segmentation with our Annual Membership: https://www.towardshealthcare.com/get-an-annual-membership
The presence of a strong pharma industry is driving the Asia Pacific.
Asia Pacific is expected to host the fastest-growing hyperlipidemia drugs market during the forecast period. The market is driven by increased disposable income, sedentary lifestyles, and the growing prevalence of hyperlipidemia. The Korean Society of Lipids and Atherosclerosis reports that hyperlipidemia affects two out of every five Korean individuals. Between 2010 and 2030, China’s cardiovascular incidents are predicted to rise by 9.2 million. The Asia-Pacific market is expanding thanks to a rise in clinical trials and research & development efforts. The development of generic medications for hyperlipidemia is accelerated by the rising demand for generic substitutes. India is the biggest manufacturer and supplier of generic medications worldwide. India exports over 40% of its generic medications worldwide. Foreign businesses are able to establish their manufacturing plants in Asia-Pacific nations due to the availability of adequate manufacturing infrastructure.
Market Segmentation
By drug class, the statins segment dominated the hyperlipidemia drugs market in 2024. People with elevated cholesterol are frequently prescribed statins by medical practitioners. Statins decrease total cholesterol and lessen the risk of stroke or heart attack. Statins come in a variety of forms. Even though they all serve the same purpose, doctors can advise experimenting with a few different alternatives to see which suits a patient the best.
By drug class, the PCSK9 inhibitors segment is estimated to grow at the fastest CAGR during the forecast period. For those who are currently approved by the FDA, using PCSK9 inhibitors would result in a lifetime net worth of $5800 per person and an estimated 1.1-year increase in life expectancy at age 51. The lifetime net benefit of PCSK9 inhibitors would be $14,100 per person if they were used in those who were at high risk for cardiovascular disease.
By route of administration, the oral segment dominated the hyperlipidemia drugs market in 2024. Because of its numerous benefits, the oral administration route is chosen above the other drug delivery administration methods. These benefits include pain avoidance, simplicity of intake, safety, high patient compliance, and adaptability to different medication kinds.
By route of administration, the parenteral segment is expected to be the fastest-growing during the forecast period. Because parenterally administered drugs are absorbed more quickly than when taken orally, their effects start sooner. Because they are processed differently and do not pass through the gastrointestinal tract’s digestive processes, they have a greater effect than oral medications.
By distribution channel, the retail pharmacies segment held the largest share of the hyperlipidemia drugs market in 2024. By interacting with the neighborhood to promote care journeys, prescription adherence, and value-based outcomes, retail pharmacists may broaden their role in healthcare.
By distribution channel, the online pharmacies segment I anticipated to grow rapidly during the forecast period. Increased accessibility to medications for persons who are confined to their homes or who reside far from a drugstore. The simplicity of comparing several websites to locate the finest deals and goods. Increased accessibility to a large range of items and convenience.
levate your healthcare strategy with Towards Healthcare. Enhance efficiency and drive better outcomes—schedule a call today: https://www.towardshealthcare.com/schedule-meeting
Competitive Landscape
Amgen, Inc., AstraZeneca, Bristol-Myers Squibb Company, Eli Lilly & Company, F. Hoffmann-La Roche Ltd., Merck, Mylan N.V., Novartis AG, Pfizer, Inc., Sanofi, Sun Pharmaceuticals Ltd., Teva Pharmaceuticals Industries Ltd., and Viatris, Inc.
Recent Developments
- In July 2024, by releasing groundbreaking recommendations for managing dyslipidemia, the Cardiological Society of India (CSI) made significant progress in using complete Indian data to address the country’s many issues and disparities in dyslipidemia prevalence.
- In November 2023, Philadelphia, Pennsylvania—The results of the REMAIN-2 trial demonstrate that in patients already receiving other lipid-lowering drugs, a new, long-acting PCSK9 inhibitor administered once every three months can drop LDL-cholesterol levels by more than 50% when compared to a placebo.
Browse More Insights of Towards Healthcare:
- Pediatric Drugs Market Size: https://www.towardshealthcare.com/insights/pediatric-drugs-market
- Diabetes Drugs Market Size: https://www.towardshealthcare.com/insights/diabetes-drugs-market
- Generic Drugs Market Size: https://www.towardshealthcare.com/insights/generic-drugs-market
- Asthma Treatment Market Size: https://www.towardshealthcare.com/insights/asthma-treatment-market
- AI in Genomics Market Size: https://www.towardshealthcare.com/insights/ai-in-genomics-market
- AI in Life Science Market Size: https://www.towardshealthcare.com/insights/ai-in-life-science-market
- Anesthesia Drugs Market Size: https://www.towardshealthcare.com/insights/anesthesia-drugs-a-numbing-agent-in-surgeries
- Asthma And COPD Drugs Market Size: https://www.towardshealthcare.com/insights/improved-asthma-and-copd-drugs-with-fewer-side-effects-are-on-the-way
- AI in Drug Discovery Market Size: https://www.towardshealthcare.com/insights/artificial-intelligence-in-drug-discovery
- Antibodies Drug Market Size: https://www.towardshealthcare.com/insights/antibodies-drug-market
Segments Covered in the Report
By Drug Class
- Statins
- Bile Acid Sequestrants
- Cholesterol Absorption Inhibitors
- Fibric Acid Derivatives
- PCSK9 Inhibitors
- Combination
- Miscellaneous
By Route of Administration
- Oral
- Parenteral
- Others
By Distribution Channel
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
By Region
- North America
- U.S.
- Canada
- Asia Pacific
- China
- Japan
- India
- South Korea
- Thailand
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Sweden
- Denmark
- Norway
- Latin America
- Brazil
- Mexico
- Argentina
- Middle East and Africa (MEA)
- South Africa
- UAE
- Saudi Arabia
- Kuwait
Discover our detailed Table of Contents (TOC) for the Hyperlipidemia Drugs Market @ https://www.towardshealthcare.com/table-of-content/hyperlipidemia-drugs-market-sizing
Invest in Our Premium Strategic Solution @ https://www.towardshealthcare.com/price/5418
You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com
Gain access to the latest insights and statistics in the healthcare industry by subscribing to our Annual Membership. Stay updated on healthcare industry segmentation with detailed reports, market trends, and expert analysis tailored to your needs. Stay ahead of the curve with valuable resources and strategic recommendations. Join today to unlock a wealth of knowledge and opportunities in the dynamic world of healthcare: Get a Subscription
About Us
Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.
Browse our Brand-New Journals:
Precedence Research | Statifacts | Towards Packaging | Towards Automotive | Towards Dental | Towards EV Solutions | Nova One Advisor | Healthcare Webwire | Packaging Webwire | Automotive Webwire
For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. IndiaShorts takes no editorial responsibility for the same.